Extended Data Table 2 Starting of symptomatic therapies – descriptive summary statistics

From: Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial

  1. MAO-B, monoamine oxidase type B; PASADENA, Phase II trial of Anti alpha-Synuclein AntiboDy in Early ParkiNson's diseAse; PPMI, Parkinson’s Progression Markers Initiative.
Back to article page